Thymosin Alpha
Thymosin Alpha
Thymosin Alpha-1 (Ta1) is a 28 amino acid peptide originally isolated from the thymus gland, recognized for its broad immunomodulatory properties. It has been investigated as an immune enhancer in chronic viral infections (hepatitis B/C, HIV/AIDS) and cri
|
Vial Size
|
Dose Range
|
Schedule
|
Primary Goal
|
|---|---|---|---|
| 10 mg vial | 300 to 500 mcg daily with gradual titration. | Daily subcutaneous injections for 8 to 12 weeks (extend to 16 weeks if desired). | Support immune modulation and enhance host defense mechanisms. |
Reconstitution Summary
Storage Summary
Thymosin Alpha
Reconstitution Steps
- Draw 1 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl until dissolved (do not shake).
- Label with reconstitution date and refrigerate at 2 to 8 °C, protected from light. At 10 mg/mL, 1 unit = 0.01 mL » 100 mcg on a U-100 insulin syringe.
How It Works
Thymosin Alpha-1 is a naturally occurring thymic peptide that modulates immune function through multiple pathways. It enhances the maturation and differentiation of T-cells, augments dendritic cell function, and promotes the production of key cytokines including interferon-a and interleukin-2. Clinical studies have demonstrated Ta1’s ability to enhance immune responses in immunocompromised individuals, including those with chronic hepatitis B and C infections. Meta-analyses have also shown benefit in reducing mortality in moderate-to-critical COVID-19 patients.
Benefits & Side Effects
Observations from preclinical and clinical literature.
- Supports enhanced T-cell function and overall immune competence.
- Demonstrates an excellent safety profile; doses up to 1.6 mg twice weekly for 6 to 12 months have been
well-tolerated. - Even at experimental doses up to 16 mg SC over 12 months, no significant Ta1-specific toxicity has
been observed. - Most common adverse effect is mild injection-site irritation (redness or discomfort)
References & Scientific Literature
- Dominari et al. Comprehensive review of Thymosin Alpha-1 mechanisms and applications (World Journal of Virology, 2020).
- Tao et al. Thymosin Alpha-1 in viral diseases (Molecules, MDPI, 2023).
- Soeroto et al. Meta-analysis of Ta1 in COVID-19 (Inflammopharmacology, 2023).
- Thymalfasin (Zadaxin) clinical overview: 1.6 mg SC twice weekly for hepatitis B (Expert Opinion on Biological Therapy).